Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGM-T1: SGM-101 tumor-targeted fluorescence endoscopy in rectal polyps with suspected T1 adenocarcinoma or high grade dysplasia
2024-510769-41-00Phase 2Completed
- Sponsor
- Leiden University Medical Center
- Start
- Oct 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sgm-101 in rectal cancer, rectal adenocarcinoma and colon adenoma, sponsored by Leiden University Medical Center. Primary endpoint: Primary ex-vivo NIR-fluorescence tumor-to-dysplasia ratio (TDR). Started Oct 2024; status: completed.
02
Drugs
sgm-101
03
Conditions
rectal cancerrectal adenocarcinomacolon adenoma
Beyond the preview
Go deeper on 2024-510769-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510769-41-00.